Zobrazeno 1 - 10
of 47
pro vyhledávání: '"Mark A. Currier"'
Autor:
Emily M. Ringwalt, Mark A. Currier, Andrea M. Glaspell, Chun-Yu Chen, Matthew V. Cannon, Maren Cam, Amy C. Gross, Matthew Gust, Pin-Yi Wang, Louis Boon, Laura E. Biederman, Emily Schwarz, Prajwal Rajappa, Dean A. Lee, Elaine R. Mardis, William E. Carson, 3rd, Ryan D. Roberts, Timothy P. Cripe
Publikováno v:
Molecular Therapy: Oncology, Vol 32, Iss 4, Pp 200886- (2024)
We previously reported that the DNA alkylator and transcriptional-blocking chemotherapeutic agent trabectedin enhances oncolytic herpes simplex viroimmunotherapy in human sarcoma xenograft models, though the mechanism remained to be elucidated. Here
Externí odkaz:
https://doaj.org/article/9f97543ab8ef4ba1b69298b70f6f6188
Autor:
Siddhi N. Paudel, Brian J. Hutzen, Katherine E. Miller, Elizabeth A. R. Garfinkle, Chun-Yu Chen, Pin-Yi Wang, Andrea M. Glaspell, Mark A. Currier, Emily M. Ringwalt, Louis Boon, Elaine R. Mardis, Mitchell S. Cairo, Nancy Ratner, Rebecca D. Dodd, Kevin A. Cassady, Timothy P. Cripe
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
Externí odkaz:
https://doaj.org/article/aea62abb85594bdd81547a1e4aff9626
Autor:
Siddhi N. Paudel, Brian J. Hutzen, Katherine E. Miller, Elizabeth A. R. Garfinkle, Chun-Yu Chen, Pin-Yi Wang, Andrea M. Glaspell, Mark A. Currier, Emily M. Ringwalt, Louis Boon, Elaine R. Mardis, Mitchell S. Cairo, Nancy Ratner, Rebecca D. Dodd, Kevin A. Cassady, Timothy P. Cripe
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
IntroductionMalignant peripheral nerve sheath tumors (MPNST) pose a significant therapeutic challenge due to high recurrence rates after surgical resection and a largely ineffective response to traditional chemotherapy. An alternative treatment strat
Externí odkaz:
https://doaj.org/article/30c6602860ac408d8659f1b13326bd9a
Autor:
Joseph A. Mamola, Chun-Yu Chen, Mark A. Currier, Kevin Cassady, Dean A. Lee, Timothy P. Cripe
Publikováno v:
Molecular Therapy: Oncolytics, Vol 29, Iss , Pp 118-124 (2023)
The use of oncolytic viruses (OVs) and adoptive cell therapies (ACT) have independently emerged as promising approaches for cancer immunotherapy. More recently, the combination of such agents to obtain a synergistic anticancer effect has gained atten
Externí odkaz:
https://doaj.org/article/6e5e3ef423954cc8a6709b96845317d9
Endogenous retrovirus envelope as a tumor-associated immunotherapeutic target in murine osteosarcoma
Autor:
Mary Frances Wedekind, Katherine E. Miller, Chun-Yu Chen, Pin-Yi Wang, Brian J. Hutzen, Mark A. Currier, Brooke Nartker, Ryan D. Roberts, Louis Boon, Joe Conner, Stephanie LaHaye, Benjamin J. Kelly, David Gordon, Peter White, Elaine R. Mardis, Timothy P. Cripe
Publikováno v:
iScience, Vol 24, Iss 7, Pp 102759- (2021)
Summary: Osteosarcoma remains one of the deadliest cancers in pediatrics and young adults. We administered two types of immunotherapies, oncolytic virotherapy and immune checkpoint inhibition, to two murine osteosarcoma models and observed divergent
Externí odkaz:
https://doaj.org/article/42684aaa1ef54305b26e4df761b4bd3f
Autor:
Nicholas L. Denton, Chun-Yu Chen, Brian Hutzen, Mark A. Currier, Thomas Scott, Brooke Nartker, Jennifer L. Leddon, Pin-Yi Wang, Rachelle Srinivas, Kevin A. Cassady, William F. Goins, Timothy P. Cripe
Publikováno v:
Molecular Therapy: Oncolytics, Vol 11, Iss , Pp 62-74 (2018)
Ewing sarcoma is a highly aggressive cancer that promotes the infiltration and activation of pro-tumor M2-like macrophages. Oncolytic virotherapy that selectively infects and destroys cancer cells is a promising option for treating Ewing sarcoma. The
Externí odkaz:
https://doaj.org/article/281c1f4c083149c8892aad55a48a285f
Autor:
Timothy P. Cripe, Peter W. Gunning, Edna C. Hardeman, Vera B. Dugina, Irina B. Alieva, Jun Zeng, Herbert Treutlein, Nina Kloss, David W. Eaves, Brooke A. Nartker, David Brown, Andrew Heaton, Eleanor Eiffe, Jeff Hook, Duo Chen, Ashleigh Swain, Justine R. Stehn, Mark A. Currier
Supplementary Materials and Methods; Figure S1. Western blot of tropomyosin isoforms in neuroblastoma cells used in this project; Figure S2. Effect of combining tropomyosin and microtubule inhibitors on cell growth; Figure S3. A, B, Effect of TR100 o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cbcb48ec37c05169fe0dec295c0792c7
https://doi.org/10.1158/1535-7163.22507779.v1
https://doi.org/10.1158/1535-7163.22507779.v1
Autor:
Timothy P. Cripe, Peter W. Gunning, Edna C. Hardeman, Vera B. Dugina, Irina B. Alieva, Jun Zeng, Herbert Treutlein, Nina Kloss, David W. Eaves, Brooke A. Nartker, David Brown, Andrew Heaton, Eleanor Eiffe, Jeff Hook, Duo Chen, Ashleigh Swain, Justine R. Stehn, Mark A. Currier
Actin filaments, with their associated tropomyosin polymers, and microtubules are dynamic cytoskeletal systems regulating numerous cell functions. While antimicrotubule drugs are well-established, antiactin drugs have been more elusive. We previously
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::784455f96f8547a82cee2cae5124a729
https://doi.org/10.1158/1535-7163.c.6538785.v1
https://doi.org/10.1158/1535-7163.c.6538785.v1
Autor:
Timothy P. Cripe, Joe Conner, Robert Spavin, Kathleen Simpson, Marianne Brunner, Beth Stockman, Lori R. Backus, Devon J. Dishman, Kristy Ott-Napier, Melinda Triplet, Michele R. Vaughan, Alexander J. Towbin, John M. Racadio, Patrick S. Warren, Mark A. Currier, James I. Geller, Keri A. Streby
Supplementary Table S1. Dose administered based on post-injection titers.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::74b0b32762cb0bc9801dc30b0ef67c18
https://doi.org/10.1158/1078-0432.22466724
https://doi.org/10.1158/1078-0432.22466724
Autor:
Timothy P. Cripe, Joe Conner, Robert Spavin, Kathleen Simpson, Marianne Brunner, Beth Stockman, Lori R. Backus, Devon J. Dishman, Kristy Ott-Napier, Melinda Triplet, Michele R. Vaughan, Alexander J. Towbin, John M. Racadio, Patrick S. Warren, Mark A. Currier, James I. Geller, Keri A. Streby
Purpose: HSV1716 is an oncolytic herpes simplex virus-1 (HSV-1) studied in adults via injection into the brain and superficial tumors. To determine the safety of administering HSV1716 to pediatric patients with cancer, we conducted a phase I trial of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0c03d81186256f1fe1e3d21f5dfaed99
https://doi.org/10.1158/1078-0432.c.6526407.v1
https://doi.org/10.1158/1078-0432.c.6526407.v1